Idorsia Ltd (IDRSF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.05 Billion CHF | -2.11% |
| 2022 | 1.08 Billion CHF | 1.81% |
| 2021 | 1.06 Billion CHF | 113.63% |
| 2020 | 497.17 Million CHF | 34.99% |
| 2019 | 368.31 Million CHF | 261.74% |
| 2018 | -227.71 Million CHF | 11.66% |
| 2017 | -257.76 Million CHF | 40.68% |
| 2016 | -434.55 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.02 Billion CHF | 10.97% |
| 2024 Q1 | 926.47 Million CHF | -12.48% |
| 2023 Q4 | 1.05 Billion CHF | 5.85% |
| 2023 Q2 | 1.2 Billion CHF | 18.83% |
| 2023 FY | 1.05 Billion CHF | -2.11% |
| 2023 Q1 | 1.01 Billion CHF | -6.29% |
| 2023 Q3 | 1 Billion CHF | -16.95% |
| 2022 Q2 | 969.2 Million CHF | -7.89% |
| 2022 Q4 | 1.08 Billion CHF | 22.1% |
| 2022 FY | 1.08 Billion CHF | 1.81% |
| 2022 Q1 | 1.05 Billion CHF | -0.93% |
| 2022 Q3 | 885.61 Million CHF | -8.62% |
| 2021 Q1 | 510.17 Million CHF | 2.61% |
| 2021 FY | 1.06 Billion CHF | 113.63% |
| 2021 Q4 | 1.06 Billion CHF | -6.28% |
| 2021 Q3 | 1.13 Billion CHF | 138.6% |
| 2021 Q2 | 474.96 Million CHF | -6.9% |
| 2020 Q4 | 497.17 Million CHF | 2.34% |
| 2020 FY | 497.17 Million CHF | 34.99% |
| 2020 Q1 | 537.03 Million CHF | 45.81% |
| 2020 Q3 | 485.82 Million CHF | 92.86% |
| 2020 Q2 | 251.9 Million CHF | -53.09% |
| 2019 Q2 | 163.6 Million CHF | 274.57% |
| 2019 Q4 | 368.31 Million CHF | 49.4% |
| 2019 FY | 368.31 Million CHF | 261.74% |
| 2019 Q3 | 246.53 Million CHF | 50.69% |
| 2019 Q1 | -93.71 Million CHF | 58.84% |
| 2018 Q3 | -101.82 Million CHF | 58.62% |
| 2018 FY | -227.71 Million CHF | 11.66% |
| 2018 Q2 | -246.05 Million CHF | -34.93% |
| 2018 Q1 | -182.36 Million CHF | 29.25% |
| 2018 Q4 | -227.71 Million CHF | -123.63% |
| 2017 Q1 | -330.43 Million CHF | 0.0% |
| 2017 FY | -257.76 Million CHF | 40.68% |
| 2017 Q4 | -257.76 Million CHF | -36.52% |
| 2017 Q3 | -188.8 Million CHF | 23.28% |
| 2017 Q2 | -246.1 Million CHF | 25.52% |
| 2016 FY | -434.55 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | -55646.284% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -6615.562% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -263325.814% |
| SQZ Biotechnologies Company | -36.23 Million USD | 3021.171% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -47110.705% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -2373.708% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 16890.705% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -114070.619% |
| Marizyme, Inc. | 18.56 Million USD | -5600.75% |
| Genus plc | 190.6 Million USD | -455.39% |
| Pharming Group N.V. | 109.8 Million USD | -864.058% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -122955.516% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -87105.245% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -155572.647% |
| ContraFect Corporation | -6.02 Million USD | 17666.777% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -91517.399% |
| IMV Inc. | 7.67 Million USD | -13700.549% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -19140.167% |
| ONE Bio Corp. | 9.04 Million USD | -11609.844% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -8076.842% |
| Mesoblast Limited | 55.85 Million USD | -1795.108% |
| MultiCell Technologies, Inc. | 90.04 USD | -1175670712.972% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -3364.6% |
| Genscript Biotech Corporation | -1.06 Billion USD | 199.74% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -169989.208% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -104946.858% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -25605.873% |
| Biomind Labs Inc. | 711.4 Thousand USD | -148701.1% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -52844.795% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -8165.854% |
| Skye Bioscience, Inc. | -5.72 Million USD | 18602.046% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -294185.397% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -47245.865% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -757084.344% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -786131.33% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -18641.23% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -5328203.216% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 144324.214% |
| EV Biologics, Inc. | 1.36 Million USD | -77282.781% |
| Q BioMed Inc. | 4.06 Million USD | -25973.2% |
| GB Sciences, Inc. | 1.74 Million USD | -60482.86% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 576075.581% |
| CSL Limited | 10.52 Billion USD | 89.943% |
| Agentix Corp. | 37.63 Thousand USD | -2812937.124% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -1648.387% |
| Enzolytics Inc. | 981.65 Thousand USD | -107735.535% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.45 Million USD | -16309.456% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 157371.03% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -47973.712% |
| argenx SE | -2.02 Billion USD | 152.176% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -2337.201% |
| HST Global, Inc. | 96.79 Thousand USD | -1093547.268% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 2351.71% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -513230.133% |
| Halberd Corporation | 144.72 Thousand USD | -731358.461% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -14870.7% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 12074.938% |
| Zenith Capital Corp. | 10.06 Thousand USD | -10518322.099% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -38981.745% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -44265.42% |
| AVAX Technologies, Inc. | -5.9 Million USD | 18032.185% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -643374.825% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 5778973.239% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -528046.204% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | -48492.656% |
| Helix BioMedix, Inc. | -2.57 Million USD | 41289.137% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -5120.823% |
| Kadimastem Ltd | -253.1 Thousand USD | 418340.077% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | -23571.096% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -525889.049% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 80807275.573% |
| LadRx Corporation | -2.03 Million USD | 52080.855% |
| Cell Source, Inc. | 9.23 Million USD | -11366.392% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 5187154.096% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -166560.736% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -166560.736% |
| Affymax, Inc. | -5.59 Million USD | 19013.239% |
| Mobile Lads Corp. | 484.23 Thousand USD | -218508.849% |
| Itoco Inc. | 228.3 Thousand USD | -463566.586% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -778326.196% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -21255.134% |
| International Stem Cell Corporation | 2.59 Million USD | -40771.583% |
| CytoDyn Inc. | 20.26 Million USD | -5124.43% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 163612773.879% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 11421498.007% |
| Qrons Inc. | 351.42 Thousand USD | -301121.591% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -13637.007% |
| SYBLEU INC | 473.71 Thousand USD | -223362.68% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 424174.193% |
| Rebus Holdings, Inc. | 305 Thousand USD | -346973.443% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -23650.702% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1695979.342% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -48438.402% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -30726.267% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -12276.64% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -136913.255% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 84785.92% |
| Neutra Corp. | 52.18 Thousand USD | -2028324.703% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 42630.092% |
| PureTech Health plc | -167.19 Million USD | 733.13% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 432333.328% |
| IXICO plc | -4.44 Million USD | 23917.151% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -7907.973% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -1829.908% |
| CSL Limited | 10.52 Billion USD | 89.943% |
| Cellectis S.A. | -43.81 Million USD | 2515.795% |